Gavreto

Monitor for pulmonary symptoms indicative of ILD/pneumonitis; withhold therapy and evaluate if occurs. Uncontrolled hypertension: do not initiate. Optimize BP prior to initiation; monitor after 1 week, then at least monthly thereafter and as clinically indicated. Hepatotoxicity. Monitor AST/ALT prior to initiation, every 2 weeks during 1^st 3 months, then monthly thereafter and as clinically indicated. Permanently discontinue if severe or life-threatening hemorrhagic events occur. Risk of tumor lysis syndrome in those with MTC (esp. with rapidly growing tumors, high tumor burden, renal dysfunction, dehydration); monitor. Risk of impaired wound healing: withhold for ≥5 days prior to elective surgery; do not give for ≥2 weeks after major surgery and until adequate healing. Moderate (total bilirubin >1.5–3.0×ULN and any AST) or severe (total bilirubin >3.0×ULN and any AST) hepatic impairment. Embryo-fetal toxicity. Advise to use effective non-hormonal contraception during and for 2 weeks (females of reproductive potential) or 1 week (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).

Monitor for pulmonary symptoms indicative of ILD/pneumonitis; withhold therapy and evaluate if occurs. Uncontrolled hypertension: do not initiate. Optimize BP prior to initiation; monitor after 1 week, then at least monthly thereafter and as clinically indicated. Hepatotoxicity. Monitor AST/ALT prior to initiation, every 2 weeks during 1^st 3 months, then monthly thereafter and as clinically indicated. Permanently discontinue if severe or life-threatening hemorrhagic events occur. Risk of tumor lysis syndrome in those with MTC (esp. with rapidly growing tumors, high tumor burden, renal dysfunction, dehydration); monitor. Risk of impaired wound healing: withhold for ≥5 days prior to elective surgery; do not give for ≥2 weeks after major surgery and until adequate healing. Moderate (total bilirubin >1.5–3.0×ULN and any AST) or severe (total bilirubin >3.0×ULN and any AST) hepatic impairment. Embryo-fetal toxicity. Advise to use effective non-hormonal contraception during and for 2 weeks (females of reproductive potential) or 1 week (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).